Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a complex and widespread condition, still not fully understood and with no cure yet. Amyloid beta (Aβ) peptide is suspected to be a major cause of AD, and therefore, simultaneously blocking its formation and aggregation by inhibition of the enzymes BACE-1 (β-secretase) and AChE (acetylcholinesterase) by a single inhibitor may be an effective therapeutic approach, as compared to blocking one of these targets or by combining two drugs, one for each of these targets. We used our ISE algorithm to model each of the AChE peripheral site inhibitors and BACE-1 inhibitors, on the basis of published data, and constructed classification models for each. Subsequently, we screened large molecular databases with both models. Top scored molecules were docked into AChE and BACE-1 crystal structures, and 36 Molecules with the best weighted scores (based on ISE indexes and docking results) were sent for inhibition studies on the two enzymes. Two of them inhibited both AChE (IC50 between 4–7 μM) and BACE-1 (IC50 between 50–65 μM). Two additional molecules inhibited only AChE, and another two molecules inhibited only BACE-1. Preliminary testing of inhibition by F681-0222 (molecule 2) on APPswe/PS1dE9 transgenic mice shows a reduction in brain tissue of soluble Aβ42.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Compound F681-0222 (47) leveraged the functional interplay between BACE1 and AChE to decrease soluble Aβ42 levels in the brain tissue of APPswe/PS1dE9 transgenic mice.534”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [534]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
A new and rapid colorimetric determination of acetylcholinesterase activity
Ellman, G. L., Courtney, K. D., Andres, V., & Featherstone, R. M. (1961) · Biochemical Pharmacology · doi:10.1016/0006-2952(61)90145-9 · Cited by 27,126 · cited 1×
“The assay condition was used for AChE as published [76].”
MethodChicco, D., & Jurman, G. (2020) · BMC Genomics · doi:10.1186/s12864-019-6413-7 · Cited by 6,143
Comparison of the predicted and observed secondary structure of T4 phage lysozyme
Matthews, B. W. (1975) · Biochimica et Biophysica Acta (BBA) - Protein Structure · doi:10.1016/0005-2795(75)90109-9 · Cited by 5,399 · cited 1×
“That ability is expressed by the MCC value (Matthews’s correlation coefficient, Equation (1)) [47].”
BackgroundChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382 · cited 1×
“Datasets containing BACE-1 and AChE inhibitors (for homo sapiens) were downloaded from the ChEMBL database [41]: BACE-1 data in November 2012 and AChE data in February 2014.”
MethodA Fast Flexible Docking Method using an Incremental Construction Algorithm
Rarey, M., Kramer, B., Lengauer, T., & Klebe, G. (1996) · Journal of Molecular Biology · doi:10.1006/jmbi.1996.0477 · Cited by 2,827 · cited 3×
“These molecules were docked by FlexX and were given weighted scores based n both the docking results and on ISE indexes (Supplementary Excel File, Table S10E).”
MethodKnopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
ZINC: A Free Tool to Discover Chemistry for Biology
Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3001277 · Cited by 2,509 · cited 2×
“Some 200 physicochemical 2D properties were calculated by MOE (molecular operating environment, 2011 version) [44] for each molecule of the “actives” (from ChEMBL database) as well as for “inactives”, which were picked randomly from the ZINC database downloaded in 2011 [42].”
MethodDrugBank 4.0: shedding new light on drug metabolism
Law, V., Knox, C., Djoumbou, Y., Jewison, T., Guo, A. C., Liu, Y., Maciejewski, A., Arndt, D., Wilson, M., Neveu, V., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1068 · Cited by 1,993
Alzheimer Mechanisms and Therapeutic Strategies
Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758
Hawkins, P. C. D., Skillman, A. G., Warren, G. L., Ellingson, B. A., & Stahl, M. T. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100031x · Cited by 1,607 · cited 2×
“Ligand preparation, crystal structure preparation and docking were performed with OMEGA from OpenEye [59] to generate 200 conformations per molecule, using “MAKE RECEPTOR” for crystal structure editing and “OEDocking” for the actual docking [60] (Supplementary Word File, Section 1.”
MethodInfluentialStructures of Human Acetylcholinesterase in Complex with Pharmacologically Important Ligands
Cheung, J., Rudolph, M. J., Burshteyn, F., Cassidy, M. S., Gary, E. N., Love, J., Franklin, M. C., & Height, J. J. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300871x · Cited by 1,356 · cited 3×
“It is also a human enzyme with sequence differences compared to the much more abundant crystal structures of the Torpedo Californica or of mouse [62].”
BackgroundLombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
KNIME: The Konstanz Information Miner
Berthold, M. R., Cebron, N., Dill, F., Gabriel, T. R., Kötter, T., Meinl, T., Ohl, P., Sieb, C., Thiel, K., & Wiswedel, B. (2008) · Studies in Classification, Data Analysis, and Knowledge Organization · doi:10.1007/978-3-540-78246-9_38 · Cited by 1,251
Optimal classifier for imbalanced data using Matthews Correlation Coefficient metric
Boughorbel, S., Jarray, F., & El-Anbari, M. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177678 · Cited by 1,222
Polypharmacology: Challenges and Opportunities in Drug Discovery: Miniperspective
Anighoro, A., Bajorath, J., & Rastelli, G. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5006463 · Cited by 1,131 · cited 1×
“This may be a demonstration of the idea that was promoted by several multi-targeting publications [98,99], e.”
BackgroundInestrosa, N. C., Alvarez, A., Pérez, C. A., Moreno, R. D., Vicente, M., Linker, C., Casanueva, O. I., Soto, C., & Garrido, J. (1996) · Neuron · doi:10.1016/s0896-6273(00)80108-7 · Cited by 1,101 · cited 2×
“More recently, it was suggested that the “peripheral anionic site” (PAS) of AChE is involved in the aggregation and formation of toxic Aβ oligomers [11,12].”
BackgroundEvaluation of the FLEXX incremental construction algorithm for protein-ligand docking
Kramer, B., Rarey, M., & Lengauer, T. (1999) · Proteins: Structure, Function, and Genetics · doi:10.1002/(sici)1097-0134(19991101)37:2<228::aid-prot8>3.0.co;2-8 · Cited by 906 · cited 1×
“Default parameters were used according to the original FlexX paper [68].”
MethodStructure and dynamics of molecular networks: A novel paradigm of drug discovery
Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.016 · Cited by 892 · cited 1×
“However, since BACE-1 has several substrates in addition to APP, which are not to be blocked [24], we suggest testing the effect of partial BACE-1 inhibition by weaker inhibitors, if obtained, which may be very effective despite their lower affinity to the target [23,25].”
BackgroundHuman aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein
Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., & Tang, J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1456 · Cited by 776 · cited 1×
“Reaction conditions for BACE-1 inhibition measurements were used according to the supplier’s manual [73].”
MethodFrom magic bullets to designed multiple ligands
Morphy, R., Kay, C., & Rankovic, Z. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03163-0 · Cited by 729 · cited 1×
“However, designing or discovering MTDL molecules is quite challenging since they are meant to bind to two or more targets, which may require different ligand properties for binding at each binding site [13,18,19].”
BackgroundAlzheimer’s disease drug development pipeline: 2024
Cummings, J., Zhou, Y., Lee, G., Zhong, K., Fonseca, J., & Cheng, F. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12465 · Cited by 702
PDBsum: a web-based database of summaries and analyses of all PDB structures
Laskowski, R. A., Hutchinson, E. G., Michie, A. D., Wallace, A. C., Jones, M. L., & Thornton, J. M. (1997) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(97)01140-7 · Cited by 628 · cited 1×
“Out of 75 human BACE-1 crystal structures examined for their interactions with ligands by the presentations at the PDBSUM site [57], 21 structures with resolution < 2 Å and with no mutations or missing segments were selected, downloaded from PDB [58] in 2013 and superimposed in MOE to find the two most different struc…”
MethodSavelieff, M. G., Nam, G., Kang, J., Lee, H. J., Lee, M., & Lim, M. H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00138 · Cited by 581 · cited 1×
“These drugs do not cure or inhibit the development of AD, and therefore, there is a great need for new drugs that prevent, delay the onset, slow the progress or treat the symptoms of AD [4,5].”
BackgroundAlzheimer’s disease drug development pipeline: 2020
Cummings, J., Lee, G., Ritter, A., Sabbagh, M., & Zhong, K. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12050 · Cited by 557 · cited 1×
“It is estimated that more than 50 million people worldwide suffer from dementia and this number is expected to grow and involves very high costs of medical care (in the trillions of dollars) with yet no cure [5,6].”
BackgroundPolypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498 · cited 3×
“Computational methods, such as docking, pharmacophore modeling and fragment approaches, as well as classification models and combined methods were already applied to MTDL discovery [13,20,21].”
BackgroundMethodPolypharmacology – Foe or Friend?
Peters, J.-U. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400856t · Cited by 465
León, R., Garcia, A. G., & Marco‐Contelles, J. (2013) · Medicinal Research Reviews · doi:10.1002/med.20248 · Cited by 440
The importance of the domain of applicability in QSAR modeling
Weaver, S., & Gleeson, M. P. (2008) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2008.01.002 · Cited by 338 · cited 1×
“For AvI, we restricted the random picking of molecules to those that had some properties that were close to the average of each of four properties of the actives: H-bond donors and acceptors, molecular weight and calculated logP, according to the important principle of “applicability domain” [43].”
MethodDonepezil Hydrochloride (E2020) and Other Acetylcholinesterase Inhibitors
Sugimoto, H., Yamanish, Y., Iimura, Y., & Kawakami, Y. (2000) · Current Medicinal Chemistry · doi:10.2174/0929867003375191 · Cited by 324
Alvarez, A., Opazo, C., Alarcón, R., Garrido, J., & Inestrosa, N. C. (1997) · Journal of Molecular Biology · doi:10.1006/jmbi.1997.1245 · Cited by 306 · cited 2×
“More recently, it was suggested that the “peripheral anionic site” (PAS) of AChE is involved in the aggregation and formation of toxic Aβ oligomers [11,12].”
BackgroundCheung, J., Gary, E. N., Shiomi, K., & Rosenberry, T. L. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml400304w · Cited by 290 · cited 1×
“The three structures’ codes with these requirements: 4M0F, 4M0E [61] and 4EY7 [62], had chain breaks between Pro258-Asn265 and Asp494-Pro498, which are both far from the binding site.”
BackgroundAcetylcholinesterase inhibitors: novel activities of old molecules
RACCHI, M. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.027 · Cited by 288 · cited 1×
“Inhibition of the catalytic site of AChE was used in the clinic to increase the amounts of its substrate, acetylcholine, thus, improving cholinergic transmission [22].”
MethodLessons from a failed γ-secretase Alzheimer trial
De Strooper, B. (2014) · Cell · doi:10.1016/j.cell.2014.10.016 · Cited by 277
Fernández-Bachiller, M. I., Pérez, C., Monjas, L., Rademann, J., & Rodríguez-Franco, M. I. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm201460y · Cited by 268
Stachel, S. J., Coburn, C. A., Steele, T. G., Jones, K. G., Loutzenhiser, E. F., Gregro, A. R., Rajapakse, H. A., Lai, M.-T., Crouthamel, M.-C., Xu, M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049379g · Cited by 262 · cited 1×
“For validation of the inhibition, a known inhibitor, β-secretase Inhibitor IV (Merck 565788) was used; the determined IC50 value was identical to the literature data (15 nM) [74].”
MethodA Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260 · cited 1×
“However, designing or discovering MTDL molecules is quite challenging since they are meant to bind to two or more targets, which may require different ligand properties for binding at each binding site [13,18,19].”
BackgroundMultitarget Drug Discovery and Polypharmacology
Bolognesi, M. L., & Cavalli, A. (2016) · ChemMedChem · doi:10.1002/cmdc.201600161 · Cited by 231 · cited 1×
“This may be a demonstration of the idea that was promoted by several multi-targeting publications [98,99], e.”
BackgroundPiazzi, L., Cavalli, A., Colizzi, F., Belluti, F., Bartolini, M., Mancini, F., Recanatini, M., Andrisano, V., & Rampa, A. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.09.100 · Cited by 214
Multi-target design strategies for the improved treatment of Alzheimer's disease
Zhang, P., Xu, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.020 · Cited by 212 · cited 1×
“, oxo-chromene) to form one molecule with dual activity [27,28].”
BackgroundCrystal Structure of an Active Form of BACE1, an Enzyme Responsible for Amyloid β Protein Production
Shimizu, H., Tosaki, A., Kaneko, K., Hisano, T., Sakurai, T., & Nukina, N. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02185-07 · Cited by 205 · cited 1×
“The pH of maximal activity differs in that family due to cellular location and to electrostatic effects by neighbor residues, but it is clear that top activity requires one protonated and one deprotonated carboxylate group of the two Asps [91].”
BackgroundLu, S.-H., Wu, J. W., Liu, H.-L., Zhao, J.-H., Liu, K.-T., Chuang, C.-K., Lin, H.-Y., Tsai, W.-B., & Ho, Y. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-8 · Cited by 204
Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
Hemming, M. L., Elias, J. E., Gygi, S. P., & Selkoe, D. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008477 · Cited by 194 · cited 1×
“However, since BACE-1 has several substrates in addition to APP, which are not to be blocked [24], we suggest testing the effect of partial BACE-1 inhibition by weaker inhibitors, if obtained, which may be very effective despite their lower affinity to the target [23,25].”
BackgroundChongomweru, H., Kasem, A., & Newaz, S. H. S. (2019) · International Conference on Machine Learning and Soft Computing (ICMLSC) · doi:10.1145/3310986.3311023 · Cited by 182
Camps, P., Formosa, X., Galdeano, C., Muñoz-Torrero, D., Ramírez, L., Gómez, E., Isambert, N., Lavilla, R., Badia, A., Clos, M. V., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900859q · Cited by 173
The case for low-level BACE1 inhibition for the prevention of Alzheimer disease
McDade, E., Voytyuk, I., Aisen, P. S. S., Bateman, R. J., Carrillo, M. C., Strooper, B. D., Haass, C., Reiman, E. M., Sperling, R. A., Tariot, P. N., et al. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00545-1 · Cited by 162 · cited 4×
“While compound 2 showed significant reduction in the soluble Aβ42 in brain tissue, it had minimal effect on the Aβ40 soluble fraction (see Supplementary Excel File, Table S19E).”
BackgroundInfluentialCumming, J. N., Smith, E. M., Wang, L., Misiaszek, J., Durkin, J., Pan, J., Iserloh, U., Wu, Y., Zhu, Z., Strickland, C., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.013 · Cited by 160 · cited 3×
“Another publication suggested some additional representative structures for BACE1 that we avoided due to their low resolution or the presence of mutations or missing residues or lack of proper ligands: those are structures 1FKN, 1TQF, 1W51 and 1XN3 [85,90] In addition, all these structures were similar regarding the f…”
BackgroundViayna, E., Sola, I., Bartolini, M., De Simone, A., Tapia-Rojas, C., Serrano, F. G., Sabaté, R., Juárez-Jiménez, J., Pérez, B., Luque, F. J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401824w · Cited by 154
In-Silico Approaches to Multi-target Drug Discovery
Xiao, H., Shi, Z., Tan, C., Jiang, Y., Go, M., Low, B. C., & Chen, Y. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0065-2 · Cited by 153
Resistance-Resistant Antibiotics
Oldfield, E., & Feng, X. (2014) · TIPS - Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.10.007 · Cited by 124
Functionalized quinoxalinones as privileged structures with broad-ranging pharmacological activities
Jiang, X., Wu, K., Bai, R., Zhang, P., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114085 · Cited by 120 · cited 1×
“The literature search on quinoxalinone in AChE and BACE-1 inhibitors gave no results, but the quinazolinone fragment was found in some AChE inhibitors [92] and was mentioned in a patent for BACE-1 inhibitors (US 2013/0150387 A1) [93], while functionalized quinoxalinones were considered privileged scaffolds [94].”
BackgroundFang, J., Li, Y., Liu, R., Pang, X., Li, C., Yang, R., He, Y., Lian, W., Liu, A.-L., & Du, G.-H. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/ci500574n · Cited by 118 · cited 1×
“As far as we are aware, there are only a few previous studies that searched for single ligands of proteins from different families, which have very different catalytic mechanisms [77,78].”
BackgroundCoburn, C. A., Stachel, S. J., Li, Y.-M., Rush, D. M., Steele, T. G., Chen-Dodson, E., Holloway, M. K., Xu, M., Huang, Q., Lai, M.-T., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049388p · Cited by 117 · cited 2×
“Another publication suggested some additional representative structures for BACE1 that we avoided due to their low resolution or the presence of mutations or missing residues or lack of proper ligands: those are structures 1FKN, 1TQF, 1W51 and 1XN3 [85,90] In addition, all these structures were similar regarding the f…”
BackgroundSun, Q., Peng, D., Yang, S., Zhu, X., Yang, W., & Yang, G. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.06.057 · Cited by 106
Ferreira, J. P. S., Albuquerque, H. M. T., Cardoso, S. M., Silva, A. M. S., & Silva, V. L. M. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113492 · Cited by 96 · cited 1×
“, oxo-chromene) to form one molecule with dual activity [27,28].”
BackgroundGaldeano, C., Viayna, E., Sola, I., Formosa, X., Camps, P., Badia, A., Clos, M. V., Relat, J., Ratia, M., Bartolini, M., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm200840c · Cited by 95
An up-to-date overview of computational polypharmacology in modern drug discovery
Chaudhari, R., Fong, L. W., Tan, Z., Huang, B., & Zhang, S. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1767063 · Cited by 83 · cited 1×
“Computational methods, such as docking, pharmacophore modeling and fragment approaches, as well as classification models and combined methods were already applied to MTDL discovery [13,20,21].”
MethodPrati, F., Uliassi, E., & Bolognesi, M. L. (2014) · MedChemComm · doi:10.1039/c4md00069b · Cited by 77
Berg, L., Andersson, C. D., Artursson, E., Hörnberg, A., Tunemalm, A., Linusson, A., & Ekström, F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026039 · Cited by 76
Modeling the Protonation States of the Catalytic Aspartates in β-Secretase
Rajamani, R., & Reynolds, C. H. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049817j · Cited by 74
De Novo Design of Multitarget Ligands with an Iterative Fragment-Growing Strategy
Shang, E., Yuan, Y., Chen, X., Liu, Y., Pei, J., & Lai, L. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500021v · Cited by 73 · cited 1×
“As far as we are aware, there are only a few previous studies that searched for single ligands of proteins from different families, which have very different catalytic mechanisms [77,78].”
BackgroundBortolami, M., Rocco, D., Messore, A., Santo, R. D., Costi, R., Madia, V. N., Scipione, L., & Pandolfi, F. (2021) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1874344 · Cited by 73 · cited 3×
“These drugs do not cure or inhibit the development of AD, and therefore, there is a great need for new drugs that prevent, delay the onset, slow the progress or treat the symptoms of AD [4,5].”
BackgroundMikulca, J. A., Nguyen, V., Gajdosik, D. A., Teklu, S. G., Giunta, E. A., Lessa, E. A., Tran, C. H., Terak, E. C., & Raffa, R. B. (2014) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12112 · Cited by 69
Alzheimer's Disease Drug Development Pipeline 2020
Sabbagh, M. N. (2020) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2020.12 · Cited by 66
The Mechanism for the Inhibition of Acetylcholinesterases by Irinotecan (CPT-11)
Dodds, H. M., & Rivory, L. P. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.6.1346 · Cited by 64 · cited 1×
“Irinotecan (DB00762) DNAtopoisomerase, cholinesterase AChE [84] 0.”
Mohamed, T., Yeung, J. C. K., Vasefi, M., Beazely, M. A., & Rao, P. P. N. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.05.077 · Cited by 64
Darras, F. H., Wehle, S., Huang, G., Sotriffer, C., & Decker, M. W. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.06.045 · Cited by 61 · cited 2×
“Another docking study of AChE inhibitors that contain quinazolinones also found that the positively charged amine part of the molecules was docked in the CAS region, while the fused ring part of the molecules was docked in the PAS [97].”
BackgroundHassan, M., Raza, H., Abbasi, M. A., Moustafa, A. A., & Seo, S.-Y. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.115 · Cited by 61 · cited 1×
“Darifenacin was previously found as one of the best ten candidates for drug repurposing using docking methods [80].”
BackgroundGhosh, A. K., Kumaragurubaran, N., Lin, H., Lei, H., Hussain, K. A., Liu, C., Devasamudram, T., Weerasena, V., Turner, R. T., Koelsch, G., et al. (2006) · Journal of the American Chemical Society · doi:10.1021/ja058636j · Cited by 60
Gupta, S., Fallarero, A., Järvinen, P. P., Karlsson, D., Johnson, M. S., Vuorela, P. M., & Mohan, C. G. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.12.131 · Cited by 53
Computer-Aided Structure-Based Design of Multitarget Leads for Alzheimer’s Disease
Domínguez, J. L., Fernández‐Nieto, F., Castro, M., Catto, M., Paleo, M. R., Porto, S., Sardina, F. J., Brea, J. M., Carotti, A., Villaverde, M. C., et al. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci500555g · Cited by 53 · cited 1×
“Contrary to much computational work for discovering AChE inhibitors, [34–38] there are few publications on computational methods for identifying dual inhibitors of AChE and BACE-1 that were also tested in vitro [39,40].”
BackgroundProtein Flexibility in Virtual Screening: The BACE-1 Case Study
Cosconati, S., Marinelli, L., Di Leva, F. S., La Pietra, V., De Simone, A., Mancini, F., Andrisano, V., Novellino, E., Goodsell, D. S., & Olson, A. J. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300390h · Cited by 52 · cited 9×
“In order to provide such weighted scores, we picked a test set made of 46 known AChE-BACE-1 dual inhibitors from the literature [30,33,69–72] and added 150 molecules picked randomly from ZINC, which were indexed by ISE and docked to both AChE and BACE-1 structures, similarly to our screened set of molecules (Supplemen…”
BackgroundInfluentialLiu, Y., Zhang, W. Y., Li, L., Salvador, L. A., Chen, T., Chen, W., Felsenstein, K. M., Ladd, T. B., Price, A. R., Golde, T. E., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301630s · Cited by 52 · cited 7×
“In order to provide such weighted scores, we picked a test set made of 46 known AChE-BACE-1 dual inhibitors from the literature [30,33,69–72] and added 150 molecules picked randomly from ZINC, which were indexed by ISE and docked to both AChE and BACE-1 structures, similarly to our screened set of molecules (Supplemen…”
BackgroundInfluentialInfluence of the Acetylcholinesterase Active Site Protonation on Omega Loop and Active Site Dynamics
Wiesner, J., Křı́ž, Z., Kuča, K., Jun, D., & Koča, J. (2010) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2010.10507368 · Cited by 51 · cited 1×
“For the AChE selected structure, 4M0F, several important residues were assigned neutrality: [66] Asp74, Glu202, Glu292, Arg296, Glu450 and His447, and Glu334 was negatively charged.”
BackgroundEnhanced HTS Hit Selection via a Local Hit Rate Analysis
Posner, B. A., Xi, H., & Mills, J. E. J. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci900113d · Cited by 48 · cited 1×
“In AvI, the dilution of the actives with large numbers of inactives (“randoms” or “decoys”) was in order to “mimic” to some extent the process of “wet” high-throughput screening, which frequently finds a very small number of actives among a huge number of real tested compounds [46].”
BackgroundStatus and future directions of clinical trials in Alzheimer's disease
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.022 · Cited by 47
Barman, A., & Prabhakar, R. S. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200611t · Cited by 42
Sharma, B., Singh, N., Singh, M., & Jaggi, A. S. (2008) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2008.02.012 · Cited by 41 · cited 5×
“Moreover, HIV protease inhibitors were already investigated for their effect on AD and some of them affected Aβ, though not directly through BACE1 [81,82].”
BackgroundInfluentialHarel, M., Hyatt, J. L., Brumshtein, B., Morton, C. L., Yoon, K. J. P., Wadkins, R. M., Silman, I., Sussman, J. L., & Potter, P. M. (2005) · Molecular Pharmacology · doi:10.1124/mol.104.009944 · Cited by 36
Lan, X., Kiyota, T., Hanamsagar, R., Huang, Y., Andrews, S., Peng, H., Zheng, J. C., Swindells, S., Carlson, G. A., & Ikezu, T. (2012) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9304-5 · Cited by 34
Tran, T., Le, M.-T., Tran, T., Tran, T., & Thai, K. (2020) · Molecules · doi:10.3390/molecules25163644 · Cited by 32 · cited 1×
“Contrary to much computational work for discovering AChE inhibitors, [34–38] there are few publications on computational methods for identifying dual inhibitors of AChE and BACE-1 that were also tested in vitro [39,40].”
BackgroundAdvances in the identification of β-secretase inhibitors
Hamada, Y., & Kiso, Y. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.784267 · Cited by 30 · cited 2×
“A link between the length of these conformations and the molecular weights of ligands that block the catalytic machinery of BACE-1 was suggested [87].”
BackgroundSynthesis of Monomeric Derivatives To Probe Memoquin’s Bivalent Interactions
Bolognesi, M. L., Chiriano, G., Bartolini, M., Mancini, F., Bottegoni, G., Maestri, V., Czvitkovich, S., Windisch, M., Cavalli, A., Minarini, A., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200691d · Cited by 28
Quinoxaline Derivatives: Novel and Selective Butyrylcholinesterase Inhibitors
Zeb, A., Hameed, A., Khan, L. U., Khan, I., Dalvandi, K., Choudhary, M. I., & Basha, F. Z. (2014) · Medicinal Chemistry · doi:10.2174/1573406410666140526145429 · Cited by 28 · cited 1×
“However, some similar quinoxaline derivatives were found to inhibit Butyrylcholinesterase [95].”
BackgroundTarget Identification and Polypharmacology of Nutraceuticals
Dormán, G., Flachner, B., Hajdú, I., & András, C. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802147-7.00021-8 · Cited by 28 · cited 1×
“It is of interest also in the case of natural products [14].”
BackgroundSelf-citationCombining Dyad Protonation and Active Site Plasticity in BACE-1 Structure-Based Drug Design
Kacker, P., Masetti, M., Mangold, M., Bottegoni, G., & Cavalli, A. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci200366z · Cited by 27
The current landscape in Alzheimer’s disease research and drug discovery
Devenish, S. R. A. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.04.002 · Cited by 25
Chen, S., Wu, C., Lin, T., Chuang, Y., & Yang, D. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.05.012 · Cited by 24 · cited 1×
“Renin inhibitor aliskiren was also found to be effective against Aβ toxicity [83].”
BackgroundVitorović-Todorović, M. D., Cvijetić, I., Juranić, I. O., & Drakulić, B. J. (2012) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2012.08.001 · Cited by 22
Exploring Different Virtual Screening Strategies for Acetylcholinesterase Inhibitors
Mishra, N., & Basu, A. (2013) · BioMed Research International · doi:10.1155/2013/236850 · Cited by 20
Syntheses and Biological Activities of Some New 4(3H)‐Quinazolinones
Bahadur, S., & SAXENA, M. (1983) · Archiv der Pharmazie · doi:10.1002/ardp.19833161112 · Cited by 14 · cited 1×
“The literature search on quinoxalinone in AChE and BACE-1 inhibitors gave no results, but the quinazolinone fragment was found in some AChE inhibitors [92] and was mentioned in a patent for BACE-1 inhibitors (US 2013/0150387 A1) [93], while functionalized quinoxalinones were considered privileged scaffolds [94].”
BackgroundDiscovering Novel and Diverse Iron-Chelators in Silico
Basu, A., Sohn, Y., Alyan, M., Nechushtai, R., Domb, A. J., & Goldblum, A. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00450 · Cited by 10 · cited 1×
“Model 1 had similar values for MCC and AUC as model 2, but model 2 was based on a more diverse set that was known to produce more diverse candidates by screening [79] The second type of BACE-1 models, HvL, compared the class of high activity molecules (IC50 < 100 nM) to lower activity molecules (IC50 > 1000 nM).”
MethodSelf-citation
Research works printed but not linked: 1
- Deng, 2016, Design, Synthesize and Bio-Evaluate 1,2-Dihydroisoquinolin-3(4H)-One Derivates as Acetylcholinesterase and β-Secretase Dual Inhibitors in Treatment with Alzheimer’s Disease, J. Biosci. Med., 4, 112
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Alternatives of Animal Models for Biomedical Research: a Comprehensive Review of Modern Approaches
Vashishat, A., Patel, P., Gupta, G. D., & Kurmi, B. D. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10701-x · Cited by 123
“…d by I S E m o d e l s t o s e l ec t t op ca nd i d a t e s f o r do c k i ng t o c r y s t a l s t r u c t u r e s o f A C h E a nd B A C E - 1 [ 101 ] C o m pu t a ti on a l - b a s e d a ss e ss m e n t o f i n t e r ac ti on b e t w ee n m o l ec u l e s A u t o D o c k u s e d do c k i ng t…”
The link between amyloid β and ferroptosis pathway in Alzheimer’s disease progression
Majerníková, N., Marmolejo-Garza, A., Salinas, C. S., Luu, M. D. A., Zhang, Y., Trombetta-Lima, M., Tomin, T., Birner-Gruenberger, R., Lehtonen, Š., Koistinaho, J., et al. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07152-0 · Cited by 73
“However, it is unclear whether NCOA4 can bind to the cell membrane before translocating to the cytoplasm, apart from the evidence demonstrating its truncated isoform SRC3 ’ s ability to bind to the cell membrane [44].”
BackgroundAsim, A., Jastrzębski, M. K., & Kaczor, A. A. (2025) · Molecules · doi:10.3390/molecules30142975 · Cited by 46
Quang-Bao, L., Baecker, D., Dung, D. T. M., Nhung, N. P., Thuần, N. T. D., Nguyen, P. L., Dung, P. T. P., Hương, T. T. L., Rasulev, B., Casañola‐Martín, G. M., et al. (2023) · Molecules · doi:10.3390/molecules28083588 · Cited by 29
“Several machine learning (ML) techniques have been applied, including genetic function approximation (GFA) and nonlinear method, support vector machine (SVM), and artificial neural networks (ANN) [14,15].”
Method
Metadata
- Authors
- Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., Kígyós, A., Tóvári, J., & Goldblum, A.
- Affiliations
- Hebrew University of Jerusalem (IL)
- National Institute of Oncology (HU)
- TargetEx Ltd., H-2120 Dunakeszi, Hungary
- Institute of Molecular Life Sciences (HU)
- KINETO Lab Ltd., H-1032 Budapest, Hungary
- Országos Korányi Tbc és Pulmonológiai Intézet (HU)
- Corresponding author
- Goldblum, Amiram
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2022-10-28
- Volume
- 23
- Issue
- 21
- Pages
- 13098
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC9655245
- OpenAlex
- W4307945532
- Cited by
- 35
- References
- 92
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 8 · 2023: 7
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- the Research and Technology Innovation Fund (EUREKA_HU_12-1-2012-0057)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- Alzheimer's disease, amyloid-beta, acetylcholinesterase inhibitors, BACE1 inhibitors, dual enzyme inhibition, virtual screening, molecular docking, enzyme inhibition, APP/PS1 mice
- MeSH terms
- Acetylcholinesterase, Alzheimer Disease, Animals, Brain, Cholinesterase Inhibitors, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Mice, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.